I came to Genentech in 2002 after finishing my post-doctoral work in virology at UCSF. Since joining Genentech I have been working on developing antibody-drug conjugates for the treatment of cancer and bispecific antibodies that redirect immune cells to attack tumors.
Learning the complex, team-oriented process of drug development has been fun and interesting. It has been very exciting to start projects that have the potential to help people and then see that potential become a reality.
It is a great pleasure be a post doc mentor at Genentech. Training the next generation of scientists makes me a better scientist and enriches my work. And Genentech provides a unique opportunity for the post doc to do basic science while interacting with people who work in both the basic science and translational fields. I think these interactions help provide a better perspective on their work and hopefully leads to their work having a greater impact.
Blood. 2017 Feb 2;129(5):609-618.
My lab works on the development of antibody-drug conjugates (ADCs), cytotoxic drugs chemically linked to antibodies, and CD3 bispecifics for the treatment of cancer. Our goal is to provide a means to deliver chemotherapy by targeting the drug to neoplastic cells.